vs
LITHIA MOTORS INC（LAD）与美敦力（MDT）财务数据对比。点击上方公司名可切换其他公司
LITHIA MOTORS INC的季度营收约是美敦力的1.0倍（$9.2B vs $9.0B），美敦力净利率更高（15.3% vs 1.5%，领先13.8%），美敦力同比增速更快（6.6% vs 0.3%），美敦力自由现金流更多（$457.0M vs $30.5M），过去两年美敦力的营收复合增速更高（5.3% vs 3.6%）
Lithia Motors Inc.是总部位于美国俄勒冈州梅德福的全国性汽车经销商集团，按营收计算为2025年美国规模最大的汽车零售商，领先于AutoNation、潘世奇汽车集团等竞争对手。截至2024年12月31日，该公司在美、加、英三国运营459家经销网点，全球员工约3万人。
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
LAD vs MDT — 直观对比
营收规模更大
LAD
是对方的1.0倍
$9.0B
营收增速更快
MDT
高出6.4%
0.3%
净利率更高
MDT
高出13.8%
1.5%
自由现金流更多
MDT
多$426.5M
$30.5M
两年增速更快
MDT
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.2B | $9.0B |
| 净利润 | $136.9M | $1.4B |
| 毛利率 | 14.9% | 65.8% |
| 营业利润率 | 3.7% | 18.8% |
| 净利率 | 1.5% | 15.3% |
| 营收同比 | 0.3% | 6.6% |
| 净利润同比 | -36.6% | 8.2% |
| 每股收益（稀释后） | $5.90 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LADMDT
| Q4 25 | $9.2B | $9.0B | ||
| Q3 25 | $9.7B | $8.6B | ||
| Q2 25 | $9.6B | $8.9B | ||
| Q1 25 | $9.2B | $8.3B | ||
| Q4 24 | $9.2B | $8.4B | ||
| Q3 24 | $9.2B | $7.9B | ||
| Q2 24 | $9.2B | $8.6B | ||
| Q1 24 | $8.6B | $8.1B |
净利润LADMDT
| Q4 25 | $136.9M | $1.4B | ||
| Q3 25 | $217.1M | $1.0B | ||
| Q2 25 | $256.1M | $1.1B | ||
| Q1 25 | $209.5M | $1.3B | ||
| Q4 24 | $216.1M | $1.3B | ||
| Q3 24 | $209.1M | $1.0B | ||
| Q2 24 | $214.2M | $654.0M | ||
| Q1 24 | $162.6M | $1.3B |
毛利率LADMDT
| Q4 25 | 14.9% | 65.8% | ||
| Q3 25 | 15.2% | 65.0% | ||
| Q2 25 | 15.5% | 64.8% | ||
| Q1 25 | 15.4% | 66.5% | ||
| Q4 24 | 15.0% | 64.9% | ||
| Q3 24 | 15.5% | 65.1% | ||
| Q2 24 | 15.4% | 64.5% | ||
| Q1 24 | 15.6% | 65.6% |
营业利润率LADMDT
| Q4 25 | 3.7% | 18.8% | ||
| Q3 25 | 4.4% | 16.8% | ||
| Q2 25 | 4.4% | 16.1% | ||
| Q1 25 | 4.4% | 19.9% | ||
| Q4 24 | 4.5% | 19.0% | ||
| Q3 24 | 4.6% | 16.1% | ||
| Q2 24 | 4.3% | 12.3% | ||
| Q1 24 | 4.0% | 18.3% |
净利率LADMDT
| Q4 25 | 1.5% | 15.3% | ||
| Q3 25 | 2.2% | 12.1% | ||
| Q2 25 | 2.7% | 11.8% | ||
| Q1 25 | 2.3% | 15.6% | ||
| Q4 24 | 2.4% | 15.1% | ||
| Q3 24 | 2.3% | 13.2% | ||
| Q2 24 | 2.3% | 7.6% | ||
| Q1 24 | 1.9% | 16.3% |
每股收益（稀释后）LADMDT
| Q4 25 | $5.90 | $1.07 | ||
| Q3 25 | $8.61 | $0.81 | ||
| Q2 25 | $9.87 | $0.81 | ||
| Q1 25 | $7.94 | $1.01 | ||
| Q4 24 | $8.09 | $0.99 | ||
| Q3 24 | $7.80 | $0.80 | ||
| Q2 24 | $7.87 | $0.50 | ||
| Q1 24 | $5.89 | $0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $8.3B |
| 总债务越低越好 | $9.7B | $27.7B |
| 股东权益账面价值 | $6.6B | $48.7B |
| 总资产 | $25.1B | $91.3B |
| 负债/权益比越低杠杆越低 | 1.47× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资LADMDT
| Q4 25 | — | $8.3B | ||
| Q3 25 | $206.5M | $8.1B | ||
| Q2 25 | $202.8M | $9.0B | ||
| Q1 25 | $234.4M | $7.9B | ||
| Q4 24 | — | $8.0B | ||
| Q3 24 | $209.8M | $7.8B | ||
| Q2 24 | $516.4M | $8.0B | ||
| Q1 24 | $264.4M | $8.3B |
总债务LADMDT
| Q4 25 | $9.7B | $27.7B | ||
| Q3 25 | — | $26.2B | ||
| Q2 25 | — | $25.6B | ||
| Q1 25 | — | $24.0B | ||
| Q4 24 | $8.2B | $24.6B | ||
| Q3 24 | — | $26.3B | ||
| Q2 24 | — | $23.9B | ||
| Q1 24 | — | $24.2B |
股东权益LADMDT
| Q4 25 | $6.6B | $48.7B | ||
| Q3 25 | $6.8B | $47.9B | ||
| Q2 25 | $7.0B | $48.0B | ||
| Q1 25 | $6.8B | $49.4B | ||
| Q4 24 | $6.7B | $48.5B | ||
| Q3 24 | $6.6B | $47.9B | ||
| Q2 24 | $6.4B | $50.2B | ||
| Q1 24 | $6.4B | $51.8B |
总资产LADMDT
| Q4 25 | $25.1B | $91.3B | ||
| Q3 25 | $24.5B | $91.0B | ||
| Q2 25 | $24.2B | $91.7B | ||
| Q1 25 | $23.5B | $90.0B | ||
| Q4 24 | $23.1B | $90.0B | ||
| Q3 24 | $23.3B | $89.7B | ||
| Q2 24 | $23.2B | $90.0B | ||
| Q1 24 | $22.2B | $90.8B |
负债/权益比LADMDT
| Q4 25 | 1.47× | 0.57× | ||
| Q3 25 | — | 0.55× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | 1.23× | 0.51× | ||
| Q3 24 | — | 0.55× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $123.7M | $925.0M |
| 自由现金流经营现金流 - 资本支出 | $30.5M | $457.0M |
| 自由现金流率自由现金流/营收 | 0.3% | 5.1% |
| 资本支出强度资本支出/营收 | 1.0% | 5.2% |
| 现金转化率经营现金流/净利润 | 0.90× | 0.67× |
| 过去12个月自由现金流最近4个季度 | $5.8M | $5.2B |
8季度趋势，按日历期对齐
经营现金流LADMDT
| Q4 25 | $123.7M | $925.0M | ||
| Q3 25 | $-98.4M | $1.1B | ||
| Q2 25 | $9.3M | $2.5B | ||
| Q1 25 | $322.1M | $2.6B | ||
| Q4 24 | $61.8M | $958.0M | ||
| Q3 24 | $219.3M | $986.0M | ||
| Q2 24 | $-148.4M | $2.8B | ||
| Q1 24 | $292.4M | $2.5B |
自由现金流LADMDT
| Q4 25 | $30.5M | $457.0M | ||
| Q3 25 | $-207.3M | $584.0M | ||
| Q2 25 | $-70.8M | $2.1B | ||
| Q1 25 | $253.4M | $2.1B | ||
| Q4 24 | $-17.7M | $554.0M | ||
| Q3 24 | $157.1M | $466.0M | ||
| Q2 24 | $-278.5M | $2.4B | ||
| Q1 24 | $212.8M | $2.1B |
自由现金流率LADMDT
| Q4 25 | 0.3% | 5.1% | ||
| Q3 25 | -2.1% | 6.8% | ||
| Q2 25 | -0.7% | 23.2% | ||
| Q1 25 | 2.8% | 25.3% | ||
| Q4 24 | -0.2% | 6.6% | ||
| Q3 24 | 1.7% | 5.9% | ||
| Q2 24 | -3.0% | 27.4% | ||
| Q1 24 | 2.5% | 26.3% |
资本支出强度LADMDT
| Q4 25 | 1.0% | 5.2% | ||
| Q3 25 | 1.1% | 5.9% | ||
| Q2 25 | 0.8% | 5.1% | ||
| Q1 25 | 0.7% | 5.7% | ||
| Q4 24 | 0.9% | 4.8% | ||
| Q3 24 | 0.7% | 6.6% | ||
| Q2 24 | 1.4% | 5.0% | ||
| Q1 24 | 0.9% | 4.3% |
现金转化率LADMDT
| Q4 25 | 0.90× | 0.67× | ||
| Q3 25 | -0.45× | 1.05× | ||
| Q2 25 | 0.04× | 2.39× | ||
| Q1 25 | 1.54× | 1.99× | ||
| Q4 24 | 0.29× | 0.75× | ||
| Q3 24 | 1.05× | 0.95× | ||
| Q2 24 | -0.69× | 4.25× | ||
| Q1 24 | 1.80× | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAD
暂无分部数据
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
